Synspira Announces $8 Million in Funding and Board of Directors

07:00 EDT 29 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
- Synspira raises $8M in funding to advance lead program, a novel cystic fibrosis therapy, into the clinic - Synspira, a privately held company developing a new class of glycopolymer-based therapeutics for pulmonary disease,...

Other Sources for this Article

MacDougall Biomedical Communications
Amanda Houlihan, 781-235-3060


More From BioPortfolio on "Synspira Announces $8 Million in Funding and Board of Directors"

Quick Search


Relevant Topics

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...